Month: May 2024

Enlarge / An image Illya Sutskever tweeted with this OpenAI resignation announcement. From left to right: New OpenAI Chief Scientist Jakub Pachocki, President Greg Brockman, Sutskever, CEO Sam Altman, and CTO Mira Murati. (credit: Ilya Sutskever / X)

On Tuesday evening, OpenAI chief scientist Ilya Sutskever announced that he is leaving the company he co-founded, six months since he participated in the coup that temporarily ousted OpenAI CEO Sam Altman. Jan Leike, a fellow member of Sutskever's Superalignment team, is reportedly resigning with him.

"After almost a decade, I have made the decision to leave OpenAI," Sutskever tweeted. "The company’s trajectory has been nothing short of miraculous, and I’m confident that OpenAI will build AGI that is both safe and beneficial under the leadership of @sama, @gdb, @miramurati and now, under the excellent research leadership of @merettm. It was an honor and a privilege to have worked together, and I will miss everyone dearly."

Sutskever has been with the company since its founding in 2015 and is widely seen as one of the key engineers behind some of OpenAI's biggest technical breakthroughs. As a former OpenAI board member, he played a key role in the removal of Sam Altman as CEO in the shock firing last November. While it later emerged that Altman's firing primarily stemmed from a power struggle with former board member Helen Toner, Sutskever sided with Toner and personally delivered the news to Altman that he was being fired on behalf of the board.

Enlarge / Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. (credit: Getty | Michael Siluk)

A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drug—about one year and three months—but then hit a plateau or "set point." But that early weight loss was generally maintained for up to four years while people continued taking the weekly injections.

The findings, published Monday in Nature Medicine, come from a fresh analysis of data from the SELECT trial, which was designed to look at the drug's effects on cardiovascular health. The trial—a multicenter, double-blind, randomized, placebo-controlled trail—specifically enrolled people with existing cardiovascular disease who also had overweight or obesity, but did not have diabetes. In all, the trial included 17,604 people from 41 countries. Seventy-two percent of them were male, 84 percent were white, and the average age was about 62 years old.

Last year, researchers published the trial's primary results, which showed that semaglutide reduced participants' risk of heart attack, stroke, and cardiovascular-related deaths by 20 percent over the span of a little over three years.

The second season of House of the Dragon premieres in about a month and we've got one final action-packed trailer to boost anticipation. While the first season felt smaller and quieter—in a good way, more focused on character relationships and political maneuvering—the show seems to be pulling out all the stops in S2 as all-out war breaks out in the legendary "Dance of Dragons."

As previously reported, the series is set nearly 200 years before the events of Game of Thrones and chronicles the beginning of the end of House Targaryen's reign. The primary source material is Fire and Blood, a fictional history of the Targaryen kings written by George R.R. Martin. As book readers know, those events culminated in a civil war and the extinction of the dragons—at least until Daenerys Targaryen came along.

(Spoilers for S1 below.)